
Oryzon Genomics Investor Relations Material
Latest events
Access the full event backlog
Slides, Transcripts, and Reports from 12,000+ public companies
Latest reports from Oryzon Genomics S.A.
Access all reports
Oryzon Genomics S.A. is a Spain-based clinical-stage biopharmaceutical company focused on the discovery and development of epigenetic therapies. The company develops small molecule inhibitors targeting specific enzymes involved in gene expression regulation, with therapeutic programs in oncology and neurodegenerative diseases. Oryzon conducts both preclinical and clinical trials and collaborates with academic and industry partners to advance its drug candidates. The company is headquartered in Barcelona, Spain, and its shares are listed on the BME.
Latest articles
)
Moncler: From the Mountains to the Runway
The story of Moncler, all the way from its beginnings in the Alps to its journey to some of the most prestigious runways in the world.
16 Apr 2025
)
eToro: Innovation, Growth, and IPO Plans
eToro was founded in 2007 and has grown into a global trading platform with over 40 million users and an extensive offering across several asset classes.
10 Apr 2025
)
Yum! Brands: The Company Behind Pizza Hut, KFC, and Taco Bell
Yum! Brands started at PepsiCo in the 1970s and is home to some of the most well-known brands in the world, such as Pizza Hut, KFC, and Taco Bell.
9 Apr 2025
Ticker symbol
ORY
Country
🇪🇸 Spain